{"filings":[{"id":1002556,"accession_number":"0001493152-26-028322","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2026-06-11T21:23:25+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Palisade Bio appoints Jordan Zwick to board; shareholders approve 50% share increase to 450M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jordan Zwick appointed to board, effective June 10, 2026; board expanded from five to six members.","Zwick received initial RSU grant of $566,000, vesting in three equal annual installments.","Stockholders approved amendment to increase authorized common shares from 300M to 450M, effective June 11, 2026.","Stockholders approved Amended and Restated 2021 Equity Incentive Plan (42.257M shares) and Employee Stock Purchase Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40606,"accession_number":"0001357459-26-000011","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2026-05-12T20:14:35+00:00","items":["2.02","9.01"],"status":"ready","headline":"Palisade Bio Q1 2026: Cash $132.6M; R&D spend up 6.4x; PALI-2108 Phase 2 UC starts Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents of $132.6M at March 31, 2026, sufficient through Phase 2 UC readout (2H 2027) and CD readout (early 2028).","R&D expense $6.4M in Q1 2026 vs $1.0M in Q1 2025 (+$5.4M) driven by PALI-2108 clinical and CMC costs.","G&A expense $4.4M in Q1 2026 vs $1.4M in Q1 2025 (+$3.0M) on higher employee costs and professional fees.","Completed Phase 1a/b for PALI-2108; Phase 1b FSCD cohort showed sustained exposure above IC90 and modulation of inflammatory/fibrotic pathways.","IND for Phase 2 UC expected 2Q 2026; Phase 2 UC trial start Q3 2026; Phase 2 CD trial start Q1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92388,"accession_number":"0001493152-26-014822","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Palisade Bio signs enrollment deal with Iterative Health, issues $3M stock to affiliate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered MSA with Iterative Health to assist with patient enrollment for Phase 2 study of PALI-2108 in ulcerative colitis.","Issued 1,536,885 shares at $1.952/share (5-day VWAP) for total $3.0 million to an affiliate of Iterative Health.","Funds support accelerated enrollment; shares sold in private placement exempt from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119461,"accession_number":"0001493152-25-026195","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Palisade Bio shareholders approve increase in authorized shares to 300M and warrant issuance of up to 8.64M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 280M to 300M shares via certificate of amendment filed Dec. 3, 2025.","Stockholders approved issuance of up to 8,637,810 common shares underlying warrants under July 23, 2025 inducement agreement.","Proposal passed with ~126.3M votes for; quorum of 85.53% of outstanding shares (148.96M) represented.","Warrant exercise required under Nasdaq Listing Rule 5635 because shares exceed 20% of pre-issuance outstanding.","Adjournment proposal also approved to allow further solicitation if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119460,"accession_number":"0001493152-25-018922","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Palisade Bio terminates phantom equity plan; unvested awards for CEO, CMO, and SVP of Finance cancelled","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Phantom Unit Plan adopted Sept 4, 2025 terminated Oct 22, 2025.","Unvested Phantom Units for CEO J.D. Finley, CMO Mitchell Jones, SVP Finance Ryker Willie cancelled for no consideration.","No specific number of units or value disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119459,"accession_number":"0001493152-25-018684","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Palisade Bio shareholders approve reverse stock split of 1:5 to 1:50, board to decide ratio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three directors re-elected: J.D. Finley (647,086 votes for), Donald Williams (641,789), Emil Chuang (659,895); each had 2,849,169 broker non-votes.","Baker Tilly ratified as auditor for FY2025 with 3,348,348 votes for, 108,424 against.","Reverse stock split amendment approved 2,353,265 for to 1,122,616 against; board may set ratio 1:5 to 1:50, implement by Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119458,"accession_number":"0001493152-25-018324","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Palisade Bio regains Nasdaq minimum bid price compliance; reports $133.3M cash","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq compliance letter confirming regained bid price requirement; matter closed as of Oct 15, 2025.","Cash and cash equivalents approx. $133.3 million as of Oct 15, 2025.","Outstanding common shares: 133,002,572; pre-funded warrants for 73,271,424 shares.","No other material corporate updates provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119457,"accession_number":"0001493152-25-017630","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palisade Bio cancels special stockholder meeting, withdraws proposals due to lack of quorum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting scheduled for Oct. 10, 2025 cancelled after failure to achieve quorum at prior adjournments.","Proposals in definitive proxy statement filed Aug. 18, 2025 are withdrawn.","Meeting was previously adjourned on Sept. 26, 2025 without business due to insufficient proxies.","Company states it still has not received proxies constituting a quorum as of today."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136024,"accession_number":"0001493152-25-015775","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Palisade Bio adjourns special meeting due to lack of quorum; reconvenes Oct 10","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting on Sep 26, 2025 lacked quorum, adjourned without conducting business.","Adjourned meeting will reconvene on Friday, Oct 10, 2025 at 10:00 a.m. PT.","Record date remains July 28, 2025; no changes to proposals.","Stockholders who previously voted need not take action if no change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136023,"accession_number":"0001493152-25-014071","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Palisade Bio adjourns special meeting due to lack of quorum; reconvenes Sept 26, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting of stockholders convened Sept 18, 2025, adjourned without business due to insufficient quorum.","Adjourned meeting will reconvene on Friday, September 26, 2025 at 10:00 a.m. Pacific Time.","Record date remains July 28, 2025; no changes to proposals or proxy instructions.","Stockholders who already voted do not need to take any action; votes can be cast via proxy or online platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136022,"accession_number":"0001493152-25-012687","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Palisade Bio adopts Phantom Unit Plan, grants 10M cash-settled units, amends exec employment agreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phantom Unit Plan approved; up to 10,000,000 cash-settled phantom units may be granted.","CEO J.D. Finley granted 323,400 Phantom Units; CMO Mitchell Jones 289,000; SVP Ryker Willie 137,600.","Board Chair granted 64,400 units; each other independent director granted 37,600 units.","Executives' phantom units vest quarterly over 3 years; directors vest annually over 3 years.","Amended employment agreements: CEO base $575K, CMO $440K, SVP Finance $298.5K, with enhanced severance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136021,"accession_number":"0001641172-25-020896","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Palisade Bio announces $3.9M warrant exercise; issues new warrants for up to 8.6M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing warrant holders exercised 4,318,905 shares at reduced price $0.9047 (from $1.40); gross proceeds ~$3.9M.","Holders receive new unregistered warrants to purchase up to 8,637,810 shares at $0.9047, 5-year term, exercisable after stockholder approval.","Company to seek stockholder approval within 60 days; new warrants include cashless exercise after 6 months if registration not effective.","Pays placement agent Ladenburg Thalmann 8% cash fee plus 6% warrants; net proceeds for working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136020,"accession_number":"0001641172-25-018313","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Palisade Bio appoints Emil Chuang to board; Fischbein resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Margery Fischbein resigned from board effective July 2, 2025; no disagreement with company.","Board accelerated vesting of Fischbein's 3,100 outstanding stock options to fully vested.","Emil Chuang, MB BS FRACP, appointed to board effective July 7, 2025; also joins audit, compensation, governance committees.","Chuang is a pediatric gastroenterologist with nearly 25 yrs experience, contributed to two NDA/sBLA approvals.","Chuang granted non-statutory stock option to purchase 8,000 shares at closing price on grant date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153056,"accession_number":"0001641172-25-008346","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Palisade Bio receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice dated April 30, 2025, due to bid price closing below $1.00 for 30 consecutive trading days.","Company has 180 calendar days to regain compliance by closing at $1.00+ for 10 consecutive business days.","If unmet, may qualify for an additional 180-day period if other listing standards are satisfied.","Stock continues to trade on Nasdaq Capital Market under symbol PALI; no immediate delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188840,"accession_number":"0001493152-24-050203","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Palisade Bio Closes $5M Underwritten Public Offering of Units and Warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 158,000 Class A Units (common + warrant) and 3,120,688 Class B Units (prefunded warrant + warrant) at $1.525/$1.5249 per unit.","Gross proceeds $5 million; net proceeds approximately $4.1 million after underwriting discounts and expenses.","Proceeds to fund Phase 1 trial of PALI-2108, pre-clinical studies, R&D, and working capital.","Repriced approximately 1,040,217 previously issued warrants to $1.40 per share for participating investor.","Underwriter Ladenburg Thalmann & Co. Inc.; 45-day overallotment option for up to 491,803 additional shares/warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205318,"accession_number":"0001493152-24-038547","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Palisade Bio revises CEO/CFO J.D. Finley's employment agreement; salary unchanged","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary stays at $542,000 per year; target bonus remains up to 50% of base.","Non-CIC severance: 12 months base salary continuation plus COBRA premiums.","CIC severance: lump sum of 18 months base plus 100% target bonus, 18 months COBRA, full acceleration of time-based equity.","Agreement is at-will; executive must sign release for severance benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205317,"accession_number":"0001493152-24-026504","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Palisade Bio stockholders elect directors and ratify Baker Tilly as auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["J.D. Finley elected director: 141,074 votes for, 11,984 withheld, 227,228 broker non-votes.","Donald Williams elected director: 139,029 votes for, 14,029 withheld, 227,228 broker non-votes.","Margery Fischbein elected director: 142,588 votes for, 10,470 withheld, 227,228 broker non-votes.","Ratification of Baker Tilly as auditor for 2024: 370,358 for, 7,697 against, 2,231 abstain, no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222209,"accession_number":"0001493152-24-018687","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Palisade Bio appoints Margery Fischbein to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Margery Fischbein appointed to the Board effective May 7, 2024; increases Board to 4 directors.","Determined independent per SEC and Nasdaq rules; appointed to Audit Committee.","Received option to purchase 1,000 shares at $7.90, vesting quarterly over 3 years.","Fischbein is Managing Director at Cassel Salpeter & Co.; previously headed healthcare investment banking at Seaport Global and FBR.","Press release issued May 7, 2024 announcing the appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222208,"accession_number":"0001493152-24-017739","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Palisade Bio announces $4M private placement of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $4M from sale of 615,242 shares/pre-funded warrants at $6.5015 each.","Issuing 922,863 common warrants with 7-year term at $6.314 per share.","Ladenburg Thalmann as placement agent; closing on or about May 6, 2024.","Net proceeds for working capital and general corporate purposes.","Company to file registration statement for resale within 10 days post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222207,"accession_number":"0001493152-24-014253","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palisade Bio details PALI-2108 development for ulcerative colitis at IBD conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PALI-2108 is a colon-specific PDE4 inhibitor prodrug for moderate-to-severe ulcerative colitis.","Phase 1 clinical study planned to begin before year-end 2024.","Development supported by $500,000 research agreement with Giiant from the Crohn's & Colitis Foundation.","Presentation given at IBD Innovate in Cambridge, MA on April 9-10, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222206,"accession_number":"0001493152-24-013336","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Palisade Bio completes 1-for-15 reverse stock split to meet Nasdaq minimum bid price","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["1-for-15 reverse split effective April 5, 2024; shares reduced from 12,771,015 to ~851,401.","Split approved by shareholders on March 25, 2024; trading begins split-adjusted April 8 under PALI.","Primary purpose: increase per-share price to regain compliance with Nasdaq's $1.00 minimum bid requirement.","No fractional shares issued; cash paid in lieu of fractional interests.","Conversion/exercise prices of preferred stock, warrants, and options proportionally adjusted by factor of 15."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241720,"accession_number":"0001493152-24-011527","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["2.02","3.01","5.07","9.01"],"status":"ready","headline":"Palisade Bio FY2023 net loss $13.1M; Nasdaq audit committee shortfall; reverse split approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents $12.5M at Dec 31, 2023; sufficient to fund operations into Q1 2025.","Net operating loss $13.1M for FY2023 vs $15.7M in FY2022; R&D expense $6.9M, G&A $6.2M.","Nasdaq notice on Mar 22, 2024 for audit committee only 2 of 3 required independent directors; cure period to Mar 4, 2025 or next annual meeting.","Shareholders approved reverse stock split (1:2 to 1:15) at Mar 25, 2024 special meeting; board may implement before Dec 31, 2024.","On track to initiate Phase 1 study of PALI-2108 for ulcerative colitis by end of 2024; IND/CTA-enabling tox studies expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241719,"accession_number":"0001493152-24-009042","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Palisade Bio director Mary Ann Gray resigns; board adopts declassified structure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director Mary Ann Gray resigned effective March 4, 2024, with no disagreement with company.","Board adopted amended bylaws removing classified board structure; directors will now be elected annually.","Change to annual director elections takes effect at the 2024 annual meeting of shareholders.","Other minor administrative amendments were also made to the bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241718,"accession_number":"0001493152-24-006132","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Palisade Bio reduces board from 8 to 4; four directors resign, Chairman changed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Directors James Neal, Stephanie Diaz, Cristina Csimma, Robert Trenschel resigned immediately; no disagreement cited.","Board cut from 8 to 4 members; Donald Williams appointed Chairman.","Recent warrant exercise generated $2.5 million gross proceeds.","PALI-2108 Phase 1 study on track to start before end of 2024; IND/CTA submission planned by year end.","Positive preclinical data presented at 2024 Crohn's & Colitis Congress; second milestone payment received from IBD Ventures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241717,"accession_number":"0001493152-24-004539","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Palisade Bio exercises warrants for $2.5M gross proceeds; exercise price reduced to $0.7313","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exercise of ~3.4M Existing Warrants at reduced price of $0.7313 per share, raising ~$2.5M gross.","Replacement Warrants issued for each exercised warrant, exercisable at $0.7313 for 5 years.","Existing warrants initially had exercise prices up to $35.525/share; investors received new warrants.","Ladenburg Thalmann acted as placement agent, earning 7.75% cash fee and 6% warrant coverage.","Net proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241716,"accession_number":"0001493152-24-004066","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2024-01-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Palisade Bio reports positive preclinical data for PALI-2108 UC therapy; Phase 1 planned for 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PALI-2108 showed colon-selective bioactivation with colon/plasma AUC ratio >200.","In DSS-induced UC mouse model, significant reduction in disease activity index over time.","No CNS toxicity or emesis observed in dogs at effective doses.","Company advancing PALI-2108 toward Phase 1 clinical study, expected to start in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259171,"accession_number":"0001493152-23-039651","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Palisade Bio updates corporate presentation; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Palisade Bio filed an 8-K on November 7, 2023, attaching an updated corporate presentation.","No specific financial or operational metrics were provided in the filing or available exhibit text.","The presentation is accessible on the company's website under the Investors section.","No changes to guidance, pipeline, or financial condition were announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259170,"accession_number":"0001493152-23-037881","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2023-10-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Palisade Bio receives Nasdaq notice for bid price below $1.00 per share","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Palisade Bio on Oct 19, 2023 of non-compliance with $1.00 minimum bid price rule.","Stock continues trading on Nasdaq under PALI; 180-day compliance period begins Oct 19.","If compliance not met, may qualify for additional 180 days if other listing standards are satisfied.","Company will monitor bid price and consider options to regain compliance within the period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276436,"accession_number":"0001493152-23-032278","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["1.01","5.02","3.02","8.01","9.01"],"status":"ready","headline":"Palisade Bio appoints Mitchell Jones as CMO; grants inducement options and RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mitchell Jones, M.D., Ph.D., appointed Chief Medical Officer effective Sept 5, 2023.","Herbert Slade ceased as CMO same date, will continue as consultant.","Inducement grant: 75,000 options at $0.6897/share, 54,700 RSUs; vest over 3 years.","Jones previously VP at Chemomab (CMMB), Finch Therapeutics (FNCH), Biora (BIOR); IBD expertise.","Employment: base salary $415,000, target bonus 40%, severance provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276435,"accession_number":"0001493152-23-032245","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Palisade Bio raises $1.97M in registered direct offering of 2.34M shares at $0.84/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of approximately $1.97 million from sale of 2,339,398 shares at $0.84 per share.","Offering closed on September 11, 2023; proceeds for working capital and general corporate purposes.","Ladenburg Thalmann acted as placement agent, receiving 7.75% cash fee and warrants to purchase 140,364 shares at $1.05.","Shares offered under effective shelf registration statement on Form S-3 (File No. 333-263705)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276434,"accession_number":"0001493152-23-032118","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2023-09-08T23:59:59+00:00","items":["1.01","2.01","8.01","9.01"],"status":"ready","headline":"Palisade Bio licenses Giiant Pharma's oral IBD drug candidates GT-2108 and GT-1908","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exclusive worldwide license for Giiant's targeted prodrug platform; lead asset GT-2108 for ulcerative colitis.","IND/CTA filing for GT-2108 expected by Q3 2024; development supported by $500k Crohn's & Colitis Foundation grant.","Milestone payments (cash or stock at Palisade's election) and royalty payments on sales; Palisade to fund all costs after first IND/CTA approval.","Second program GT-1908 targeting fibrostenotic Crohn's Disease via oral PDE4 compound."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294168,"accession_number":"0001493152-23-020669","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["1.01","3.02","5.02","5.07","9.01"],"status":"ready","headline":"Palisade Bio CEO gets pay raise; shareholders OK equity plan amendments increasing shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO J.D. Finley's base salary raised to $542,000 from $490,000; bonus target increased to 50% from 45%, effective June 1, 2023.","Committee approved 245,660 employee options and 112,030 RSUs; each of 7 directors gets 5,160 options or 2,580 options plus 1,880 RSUs.","Shareholders approved 2021 Equity Incentive Plan amendment, increasing authorized shares by 708,072 and annual evergreen to 7.5% from 4%.","Shareholders also approved 2021 ESPP amendment, adding 109,944 shares and raising annual increase to 2.5% from 1%.","Annual meeting elected directors Neal, Finley, Gray as Class III directors to 2026; all other proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294167,"accession_number":"0001493152-23-011066","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2023-04-05T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Palisade Bio raises $6M in registered direct offering and private placement at $2.64/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$6.0M from sale of 2,272,723 shares/pre-funded warrants at $2.64 per share.","Includes 756,317 registered shares, unregistered shares/pre-funded warrants, and 2,272,723 common warrants (exercise $2.64, 5-year term).","Ladenburg Thalmann acted as placement agent; net proceeds for working capital and general corporate purposes.","Offering closed on April 5, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314776,"accession_number":"0001493152-23-007342","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Palisade Bio confirms no deposits or investments at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company aware of FDIC takeover of SVB due to liquidity concerns.","Holds no deposits or investments at Silicon Valley Bank.","No direct financial impact from SVB failure expected.","Company's cash and operations unaffected by SVB closure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314775,"accession_number":"0001493152-23-003966","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2023-02-08T23:59:59+00:00","items":["3.02","5.02","8.01","9.01"],"status":"ready","headline":"Palisade Bio promotes Robert McRae to COO, appoints J.D. Finley to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert McRae appointed COO effective Feb 2, 2023; previously SVP of Operations and Strategic Development.","J.D. Finley (interim CEO/CFO) appointed to Board as Class III director, expanding board from 7 to 8.","Finley's base salary raised to $490K (from $440K) and target bonus increased to 45%, effective Oct 1, 2022.","Conditional equity grants to officers: 81,500 options ($2.40, 10yr), 59,500 RSUs, 68,700 PSUs; require shareholder approval.","PSUs vest 50% at $3.20 VWAP and 50% at $4.25 VWAP over 20 consecutive trading days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314774,"accession_number":"0001493152-23-000368","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Palisade Bio closes $2.5M registered direct offering and concurrent private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised approximately $2.5M gross via 1,052,631 shares/pre-funded warrants at $2.375/share plus 1,052,631 five-year warrants at $2.375.","Transaction closed January 4, 2023; Ladenburg Thalmann acted as exclusive placement agent.","Proceeds intended for working capital and general corporate purposes.","Offering includes registered direct (513,842 shares/pre-funded warrants) and unregistered private placement (538,789 pre-funded warrants).","Company agreed to file resale registration statement for underlying shares within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333168,"accession_number":"0001493152-22-035770","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palisade Bio stops Phase 2 LB1148 trial early; topline data due H1 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrolled 35 of 70 planned patients in Phase 2 PROFILE study for post-surgical adhesions; voluntarily halting further enrollment.","Of those, 31 completed first surgery and 9 completed second surgery (key inflection point for data).","Topline data from the 35 patients expected in first half of 2023.","Company designing a dose optimization study to refine dosing; enrollment anticipated in H1 2023.","CMO Herbert Slade stated collected data is sufficient for evaluation and to guide next steps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333167,"accession_number":"0001493152-22-033543","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2022-11-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Palisade Bio appoints Dr. Herbert Slade as Chief Medical Officer effective Nov 17, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Slade will serve as part-time consultant CMO with annual compensation of $240,000.","He had been consulting for the company since May 2022 and previously served as clinical advisor for LB1148.","Over 25 years of pharmaceutical/medical device leadership; previously CMO at Smith & Nephew, DFB Pharma, 3M Pharma.","No severance or termination benefits are provided in the consulting arrangement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333166,"accession_number":"0001493152-22-032591","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2022-11-16T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Palisade Bio effects 1-for-50 reverse stock split to meet Nasdaq minimum bid price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective 5:00 p.m. ET Nov 15, 2022; common stock trades on split-adjusted basis from Nov 16 under same ticker PALI.","Outstanding shares reduced from ~77.08M to ~1.54M; authorized shares decreased from 300M to 280M.","Split intended to raise per-share price above $1 to regain compliance with Nasdaq minimum bid-price listing requirement.","No fractional shares issued; cash paid in lieu based on Nov 15 closing price.","Conversion price of Series A Convertible Preferred Stock proportionately adjusted following the reverse split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333165,"accession_number":"0001493152-22-028556","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2022-10-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Palisade Bio terminates Chief Medical Officer Michael Dawson, effective Oct 11, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Dawson, MD, terminated as Chief Medical Officer effective October 11, 2022.","No successor or interim CMO named in the filing.","Departure may impact clinical development strategy for Palisade Bio (PALI)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333164,"accession_number":"0001493152-22-028453","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2022-10-14T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Palisade Bio CEO Thomas Hallam resigns; CFO JD Finley appointed interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Thomas Hallam resigned effective Oct 11, 2022; separation agreement includes $530,000 paid over 12 months, COBRA, accelerated vesting.","JD Finley, current CFO, appointed interim CEO effective Oct 10; will continue as CFO.","Company will not present at American College of Surgeons Clinical Congress 2022 to focus on internal reorganization.","Dr. Hallam's resignation not due to any disagreement on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333163,"accession_number":"0001493152-22-027885","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2022-10-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Palisade Bio shareholders approve reverse stock split (1:10-1:50) and warrant issuance of up to 110.4M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio range 1-for-10 to 1-for-50 approved at Oct 4 special meeting; 45.2M votes for, 2.9M against.","Issuance of up to 110.4M shares upon exercise of Series 1 and 2 warrants approved at Oct 6 meeting; 5.5M for, 4.0M against.","Authorized share reduction from 300M to 280M approved at Oct 6 meeting; 11.5M votes for, 1.2M against.","Reverse split must be effected before 2023 annual meeting; exact ratio set by Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350629,"accession_number":"0001493152-22-026761","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2022-09-26T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Palisade Bio dismisses BDO as auditor, appoints Baker Tilly effective Sept 21, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed BDO USA, LLP on Sept 21, 2022; no disagreements during 2020-2021 or interim 2022.","Prior BDO audit reports contained a going-concern explanatory paragraph for 2020 and 2021.","Material weaknesses in internal controls over financial reporting noted for 2021 and 2020 (financial close and option valuation).","Baker Tilly US, LLP appointed as new independent registered public accounting firm for fiscal year 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350628,"accession_number":"0001493152-22-025929","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2022-09-15T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Palisade Bio cuts workforce by 20% and identifies over $1.5M in annual cost savings to focus on LB1148","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction in force of 20% with estimated cash severance of $380,148.","Anticipates annual cost savings of ~$773,000 from workforce reduction plus up to $800,000 from other cuts, totaling >$1.5M.","Company to focus all resources on advancing lead asset LB1148, with Phase 3 enrollment targeted within 18-24 months.","Payment of severance expected to be substantially completed by end of Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350627,"accession_number":"0000950170-22-017505","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2022-08-16T23:59:59+00:00","items":["1.01","5.03","8.01","9.01"],"status":"ready","headline":"Palisade Bio closes $13.8M underwritten public offering of common stock, Series B preferred, and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$13.8M; net proceeds ~$12.2M after underwriting discounts and estimated expenses.","Issued 49.36M shares common, 1,460 shares Series B preferred (convertible into 4,000 common each), plus warrants for 55.2M shares at $0.25 exercise price.","Underwriter's over-allotment option fully exercised for an additional 7.2M common shares and warrants.","Warrants exercisable only after stockholder approval per Nasdaq rules; Series 1 expires in 1 year, Series 2 in 5 years.","Post-offering outstanding common shares: 71,240,169 (excluding 5.84M shares from Series B conversion)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350626,"accession_number":"0000950170-22-017410","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Palisade Bio reduces stockholder meeting quorum requirement from majority to one-third","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted amended bylaws on Aug 10, 2022 to lower quorum to one-third of outstanding common shares.","Change ensures company can achieve quorum at future stockholder meetings.","No material impact on business or operations expected from the bylaw amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367815,"accession_number":"0000950170-22-011498","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Palisade Bio shareholders elect two Class II directors and ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Election of Donald Williams and Robert J. Trenschel as Class II directors to serve until 2025.","Ratification of BDO USA as independent auditor for FY2022 with 8,731,767 votes for.","Advisory approval of named executive officer compensation passed with 3,765,654 votes for.","10,123,515 shares present (55.52% of outstanding); quorum achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367814,"accession_number":"0000950170-22-010416","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2022-05-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Palisade Bio receives Nasdaq bid price deficiency notice; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified on May 20, 2022 that PALI common stock closed below $1.00 minimum for 30 consecutive trading days.","Company has 180 calendar days to regain compliance; stock continues trading under symbol PALI.","Compliance achieved if closing bid price is $1.00 or more for at least 10 consecutive business days.","If deficient at end of period, additional 180 days may be available if other listing standards are met.","Company will monitor bid price and may consider options to cure deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367813,"accession_number":"0001193125-22-143832","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2022-05-06T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Palisade Bio raises ~$2.0M in registered direct offering and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 3,646,690 shares at $0.55/share for gross proceeds of ~$2.0M.","Concurrent private placement of warrants to purchase 3,646,690 shares at $0.7105, exercisable in 6 months, expiring in 5.5 years.","Placement agent Ladenburg Thalmann receives 7.75% cash fee and 218,801 warrants at $0.7105 with 5-year term.","Shares offered via effective S-3 registration statement filed March 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367812,"accession_number":"0001193125-22-143077","cik":1357459,"company_name":"PALISADE BIO, INC.","ticker":"PALI","form_type":"8-K","filed_at":"2022-05-06T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Palisade Bio raises $2.0M via registered direct offering and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3,646,690 shares at $0.55/share for gross proceeds of ~$2.0M.","Concurrent warrants to purchase 3,646,690 shares at $0.7105, exercisable in 6 months.","Closing expected on or about May 10, 2022, subject to customary conditions.","Net proceeds for working capital and development of lead candidate LB1148.","Ladenburg Thalmann acting as exclusive placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":367988880.01932365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-06T23:59:59+00:00|367812"}